DUBLIN–(BUSINESS WIRE)–The “North America Antibody Drug Conjugates Market – Forecasts from 2022 to 2027” report has been added to ResearchAndMarkets.com’s offering.
Market Drivers
The rising prevalence of cancer is the primary driver of the antibody drug conjugates market in North America. Because cancer claims millions of lives each year and is on the rise, the need for an effective treatment is greater than ever. Furthermore, rising health awareness among individuals aids in the early detection of cancer. Which can be treated promptly to prevent cancer from spreading to other regions of the body. Another aspect driving demand in the region is solid health facilities and the availability of cancer treatment.
Furthermore, the region’s growing trend towards cancer therapies, as well as active research and development, is driving the market. in addition, increased R&D in ADCs and rising healthcare expenditure on cancer therapy play a significant role in the market.
Growth Factors
Patients with Cancer Are Increasing
Cancer is the second leading cause of death in North America. Cancer is expected to kill 9.6 million people globally in 2018, according to the World Health Organization. In the USA, 1.7 million new cases of cancer were reported in the year 2018, according to the U.S. Centers for Disease Control and Prevention. The Canadian Cancer Society observed an increase in the number of cases in Canada over the past few years. Cancer is the leading cause of death in Canada, accounting for 28.2% of all deaths. On average, every day 232 Canadians die due to cancer.
With increasing awareness of cancer and rising, medical facility detection of cancer in its early-stages and early detection helps eliminate it before some serious damage is done. An increasing sedentary lifestyle, increasing consumption of junk food, tobacco and alcohol are some of the prevalent factors causing cancer. Tobacco and alcohol usage, obesity, a lack of fruits and vegetables, and a lack of physical activity are all linked to cancer fatalities.
Global R&D on ADCs is expanding.
With the increasing development in research and development by various companies to find an effective treatment for cancer, more and more companies are investing in R & D to develop such drugs. With deeper understanding and the advent of new technology, the scope of R & D in ADCs has further increased. Moreover, the approval rate for U.S. Food and Drug Association (FDA) products has increased significantly. in the year 2021, 12 ADC drugs have been approved. Further, deep research on interactions between ADCs and the immune system for potential synergistic therapeutic effects that can be used to improve the drug is taking place.
Restraint
Expensive Treatment
Cancer treatments come with a hefty price tag., due to extensive research, licensing, patents, and manufacturing costs of drugs. According to the World Health Organization (WHO), the total annual economic cost of cancer in 2010 was estimated at US$ 1.16 trillion. Antibody-drug conjugates can be an expensive treatment for cancer patients, with a high level of time and money invested in R & D adding to the cost. ADCs also have a high manufacturing cost, which adds up to the final cast. The dominant cost in the manufacturing process of raw material is depending on the nature of the toxins, the drug-linker raw material can cost between $200-$2000 per gram. Furthermore, a small batch of doses produced per year is not able to reach the economies of scale. Further, strict regulation from medical and drug authorities adds to the cost.
Segmentation:
By Product Type
- Adcetris
- Kadcyla
- Other Product Types
By Application
- Breast Cancer
- Blood Cancer
- Ovarian Cancer
- Lung Cancer
- Brain Tumor
- Others
By End-User
- Hospitals
- Clinics
- Others
By Country
- USA
- Canada
- Mexico
Key Topics Covered:
1. INTRODUCTION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
5. NORTH AMERICA ANTIBODY-DRUG CONJUGATES MARKET, BY PRODUCT TYPE
6. NORTH AMERICA ANTIBODY-DRUG CONJUGATES MARKET, BY APPLICATION
7. NORTH AMERICA ANTIBODY-DRUG CONJUGATES MARKET, BY END-USER
8. NORTH AMERICA ANTIBODY-DRUG CONJUGATES MARKET, BY GEOGRAPHY
9. COMPETITIVE INTELLIGENCE
10. COMPANY PROFILES
Companies Mentioned
- GlaxoSmithKline Plc
- Takeda Pharmaceutical Company Ltd.
- F. Hoffmann-La Roche Ltd.
- Pfizer, Inc
- AstraZeneca
- Gilead Sciences, Inc.
- Astellas Pharma
- Seagen, Inc.
- Seattle Genetics Inc.
- Genentech Inc.
- Immunogen Inc.
- MabPlex USA, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/c736jk
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900